TAMBOCOR

Dose: 0.714 to 2.857 mg/kg
Single Dose: 1.8 (1.7855)
Frequency: 12 hourly
Route: PO
Instructions: -

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose: 100 to 400 mg
Single Dose: 250 (250)
Frequency: 12 hourly
Route: PO
Instructions:

Flecainide (Acetate) also known as Apocard E-0735, Apocard E-0735. . It is of Synthetic origin and belongs to Piperidylbenzamide. It belongs to Na-Channel Antiarrhythmic antagonist pharmacological group on the basis of mechanism of action and also classified in Anti arrhythmic agents pharmacological group.The Molecular Weight of Flecainide (Acetate) is 474.40. It is weakly acidic drug and Its pKa is 9.3.

Flecainide (Acetate) is contraindicated in conditions like Cardiogenic shock,Cardiac failure,Conduction system disease.

Flecainide (Acetate) produces potentially life-threatening effects which include Conduction system disorders, Heart failure, Ventricular proarrhythmic effects. which are responsible for the discontinuation of Flecainide (Acetate) therapy.The signs and symptoms that are produced after the acute overdosage of Flecainide (Acetate) include Asystole, Respiratory paralysis.The symptomatic adverse reactions produced by Flecainide (Acetate) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Ataxia, Nausea, Anxiety, Light-headedness, Blurred vision, Metallic taste, Ataxia.

Flecainide (Acetate) is primarily indicated in conditions like Atrial fibrillation, Atrial flutter, Cardiac arrhythmia, Ventricular arrhythmias, Ventricular fibrillation, and can also be given in adjunctive therapy as an alternative drug of choice in Angina, Blood Pressure.

Flecainide (Acetate) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmiodarone (HCl)Increased plasma concentration of flecainide. Increased myocardial depression with any anti-arrhythmic. The dose of flacainide should be halved.AmprenavirAmprenavir possibly increases plasma concentration of Flecainide; increased risk of ventricular arrhythmias. ADVICE: Avoid concomitant use.MajorDisopyramideHalofantrine (HCl)NelfinavirNevirapineParoxetineRitonavirSodium CitrateSodium Citrate may decrease the excretion and increase the serum levels of Flecainide (Acetate), possibly increasing their pharmacologic effects.Verapamil (HCl)VORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tab Store Below 40°C. Protect from Sunlight and Moisture.

Patients with pacemakers (especially those who may be pacemaker dependent because stimulation threshold may rise appreciably); avoid in sinus node dysfunction, atrial conduction defects, second-degree or greater AV block, bundle branch block or distal block unless pacing rescue available; atrial fibrillation following heart surgery; elderly (accumulation may occur); hepatic impairment; renal impairment (monitor plasma-flecainide concentration); pregnancy; breast-feeding.